GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oxford BioDynamics PLC (OTCPK:OXBOF) » Definitions » Capex-to-Revenue

OXBOF (Oxford BioDynamics) Capex-to-Revenue : 0.98 (As of Sep. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Oxford BioDynamics Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Oxford BioDynamics's Capital Expenditure for the six months ended in Sep. 2024 was $-0.40 Mil. Its Revenue for the six months ended in Sep. 2024 was $0.41 Mil.

Hence, Oxford BioDynamics's Capex-to-Revenue for the six months ended in Sep. 2024 was 0.98.


Oxford BioDynamics Capex-to-Revenue Historical Data

The historical data trend for Oxford BioDynamics's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oxford BioDynamics Capex-to-Revenue Chart

Oxford BioDynamics Annual Data
Trend Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24
Capex-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.00 9.07 5.86 1.40 0.94

Oxford BioDynamics Semi-Annual Data
Sep14 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.31 1.19 1.57 0.89 0.98

Competitive Comparison of Oxford BioDynamics's Capex-to-Revenue

For the Biotechnology subindustry, Oxford BioDynamics's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oxford BioDynamics's Capex-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oxford BioDynamics's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Oxford BioDynamics's Capex-to-Revenue falls into.


;
;

Oxford BioDynamics Capex-to-Revenue Calculation

Oxford BioDynamics's Capex-to-Revenue for the fiscal year that ended in Sep. 2024 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-0.787) / 0.841
=0.94

Oxford BioDynamics's Capex-to-Revenue for the quarter that ended in Sep. 2024 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-0.401) / 0.409
=0.98

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Oxford BioDynamics  (OTCPK:OXBOF) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


Oxford BioDynamics Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Oxford BioDynamics's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Oxford BioDynamics Business Description

Traded in Other Exchanges
Address
John Smith Drive, 3140 Rowan Place, ARC Oxford, Oxford, GBR, OX4 2WB
Oxford BioDynamics PLC is a biotechnology company engaged in developing and commercializing precision clinical diagnostic tests for life-changing diseases. It has two commercially available products: the EpiSwitch PSE (EpiSwitch Prostate Cancer Detection Test) and EpiSwitch CiRT (Checkpoint Inhibitor Response Test) blood tests. The tests are based on the company's proprietary 3D genomic biomarker platform, EpiSwitch which enables screening, evaluation, validation, and monitoring of biomarkers. In addition, the company offers, EpiSwitch Explorer Array Kit for 3D genome profiling. It is also developing new tests in the areas of oncology, neurology, inflammation, hepatology, and animal health. Geographically, it derives key revenue from the United States of America.

Oxford BioDynamics Headlines

From GuruFocus